Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88215704 |
LAW OFFICE ASSIGNED |
LAW OFFICE 123 |
MARK SECTION |
MARK |
http://uspto.report/TM/88215704/mark.png (stylized and/or with design) |
STANDARD CHARACTERS |
NO |
USPTO-GENERATED IMAGE |
NO |
OWNER SECTION (current) |
NAME |
Pfizer Inc. |
MAILING ADDRESS |
235 East 42nd Street |
CITY |
New York |
STATE |
New York |
ZIP/POSTAL CODE |
10017 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
PHONE |
212-733-2323 |
FAX |
212-573-2273 |
EMAIL |
XXXX |
OWNER SECTION (proposed) |
NAME |
Pfizer Inc. |
MAILING ADDRESS |
235 East 42nd Street |
CITY |
New York |
STATE |
New York |
ZIP/POSTAL CODE |
10017 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
PHONE |
212-733-2323 |
FAX |
212-573-2273 |
EMAIL |
XXXX |
CORRESPONDENCE INFORMATION (current) |
NAME |
Richard A. Friedman |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
deadlinesipnyo@pfizer.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
NOT PROVIDED |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
Richard A. Friedman |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
deadlinesipnyo@pfizer.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
NOT PROVIDED |
DOCKET/REFERENCE NUMBER |
T424690 |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic,
immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and
viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical
preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use |
GOODS OR SERVICES |
KEEP ALL LISTED |
INTERNATIONAL CLASS |
044 |
CURRENT IDENTIFICATION |
Providing medical information in the field of oncological diseases and disorders |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
2 |
ONGOING EFFORT |
product or service research or development |
ALLOWANCE MAIL DATE |
06/18/2019 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
2 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
250 |
TOTAL AMOUNT |
250 |
SIGNATURE SECTION |
SIGNATURE |
/RAF/ |
SIGNATORY'S NAME |
Richard A. Friedman |
SIGNATORY'S POSITION |
Attorney of record, Maryland Bar member |
DATE SIGNED |
06/03/2020 |
SIGNATORY'S PHONE NUMBER |
212-733-0086 |
FILING INFORMATION |
SUBMIT DATE |
Wed Jun 03 11:35:44 ET 2020 |
TEAS STAMP |
USPTO/ESU-XXX.XXX.XX.XX-2
0200603113544428206-88215
704-710144fcb6969cc980f53
61dda4a677638818e4c25ee88
7a64dec876f2c275a874-DA-3
5430423-20200603105815475
549 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: DAURISMO (stylized and/or with design, see http://uspto.report/TM/88215704/mark.png)
SERIAL NUMBER: 88215704
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Pfizer Inc., having an address of
235 East 42nd Street
New York, New York 10017
United States
Phone: 212-733-2323
Fax: 212-573-2273
Email: XXXX
Proposed: Pfizer Inc., having an address of
235 East 42nd Street
New York, New York 10017
United States
Phone: 212-733-2323
Fax: 212-573-2273
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 06/18/2019.
For International Class 005:
Current identification: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious,
inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and
disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely,
antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
For International Class 044:
Current identification: Providing medical information in the field of oncological diseases and disorders
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development
Correspondence Information (current):
Richard A. Friedman
PRIMARY EMAIL FOR CORRESPONDENCE: deadlinesipnyo@pfizer.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED
Correspondence Information (proposed):
Richard A. Friedman
PRIMARY EMAIL FOR CORRESPONDENCE: deadlinesipnyo@pfizer.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $250 will be submitted with the form, representing payment for 2 classes.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /RAF/ Date Signed: 06/03/2020
Signatory's Name: Richard A. Friedman
Signatory's Position: Attorney of record, Maryland Bar member
Signatory's Phone: 212-733-0086
RAM Sale Number: 88215704
RAM Accounting Date: 06/03/2020
Serial Number: 88215704
Internet Transmission Date: Wed Jun 03 11:35:44 ET 2020
TEAS Stamp: USPTO/ESU-XXX.XXX.XX.XX-2020060311354442
8206-88215704-710144fcb6969cc980f5361dda
4a677638818e4c25ee887a64dec876f2c275a874
-DA-35430423-20200603105815475549